Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 28, 2026 16:05 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

Kailera will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, at 10:30 am EDT.
May 26, 2026 16:02 ET | Source: Kailera Therapeutics, Inc.

Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates

Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates
May 13, 2026 07:30 ET | Source: Kailera Therapeutics, Inc.

Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions

Hengrui Pharma and Kailera Therapeutics announce clinical data presentations at the American Diabetes Association 86th Scientific Sessions
May 07, 2026 16:10 ET | Source: Omada Health, Inc.

Omada Health Joins Lilly Employer Connect, Expanding Its Access Pathways for GLP-1 Care as Patients Seek More Lifestyle Support

Omada Health Joins Lilly Employer Connect, Expanding Its Access Pathways for GLP-1 Care as Patients Seek More Lifestyle Support
April 17, 2026 09:00 ET | Source: Omada Health, Inc.

Omada Health Helps Members on GLP‑1s Lose More Fat, Preserve Muscle Mass, and Improve Mental Health, New Study Finds

In a 12‑week study, Omada GLP‑1 Care Track members, on average, lost more weight and saw greater improvements in body composition than controls.
March 05, 2026 16:07 ET | Source: Omada Health, Inc.

Omada Health Announces GLP-1 Flex Care, Giving Employers a New, Flexible Path to Support Obesity Care

Omada Health announces GLP-1 Flex Care, giving employers a new, flexible path to support obesity care
February 10, 2026 07:00 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics and Hengrui Pharma Report Positive Topline Data from Phase 2 Obesity Trial of Oral Ribupatide

Kailera and Hengrui report positive topline data from Hengrui’s Phase 2 clinical trial of oral ribupatide, a GLP-1/GIP receptor dual agonist peptide.
November 06, 2025 16:10 ET | Source: Omada Health, Inc.

Omada Health Announces GLP-1 Prescribing Capability to Support Growing Member Population

Omada Health Announces GLP-1 Prescribing Capability to Support Growing Member Population
October 17, 2024 09:00 ET | Source: InformedDNA

Phenomix Sciences and InformedDNA Partner to Advance Genetics-Driven Obesity Care

Phenomix Sciences and InformedDNA are partnering to personalize obesity care, treatment and planning based on a patient's DNA.
March 27, 2024 17:33 ET | Source: Obesity Canada

By 2035, Canada could have the most enviable healthcare system in the world if obesity is recognized as a chronic disease, predicts Obesity Canada

Canada must recognize obesity as a chronic disease.